New Studies Reveal ColdZyme's Effectiveness Against Respiratory Infections

Recent findings from two independent studies published in The Journal of Physiology highlight the significant potential of ColdZyme in tackling respiratory infections. This medical device has emerged as a reliable solution for reducing the sick days and symptoms associated with upper respiratory infections, proving its ability to address the issue at its source.

Conducted by researchers from the University of Kent and the University of Vienna, the studies showcased ColdZyme’s efficacy in combating viruses that cause respiratory infections. The primary focus was on its ability to inhibit the infection processes within the cells, thus mitigating the spread of viruses and subsequently reducing tissue damage in the airways. This is particularly beneficial for both athletes and the general population, as emphasized by Glen Davison, a professor of Sport and Exercise Sciences at the University of Kent.

In one of the studies, 164 active athletes participated in a randomized, double-blind, placebo-controlled trial. At the first signs of upper respiratory infection symptoms, half of the participants were administered ColdZyme, while the other half received a placebo. The results were compelling: those using ColdZyme had significantly lower symptom scores and experienced fewer lost training days due to colds when compared to the placebo group. Specifically, the study indicated a dramatic 94% reduction in the viral load of rhinovirus, the primary cause of common colds, amongst those treated with ColdZyme.

Doris Wilflingseder, a professor at the Ignaz Semmelweis Institute in Vienna, further elaborated on the in vitro findings. The study demonstrated that ColdZyme effectively blocked cold viruses from adhering to human epithelial cells present in the upper respiratory tract. When exposed to rhinovirus in lab simulations, cells treated with ColdZyme exhibited significantly reduced viral loads, leading to a much lower extent of infection compared to the saline solution control group. The promising results included observations that the tissue cultures seemed nearly uninfected after treatment with ColdZyme, with intact cell nuclei and minimal remaining virus particles.

These findings are particularly noteworthy as they go beyond merely alleviating symptoms. Claus Egstrand, CEO of Enzymatica, expressed optimism regarding the independent research, noting that these studies confirm ColdZyme’s functionality in directly targeting the virus responsible for respiratory infections rather than just masking symptoms. By shortening illness duration and alleviating discomfort, ColdZyme offers valuable relief, particularly for those who normally view colds as an unavoidable issue.

Detailed graphical data revealed several key results:
1. Viral Load Reduction: Participants in the ColdZyme group exhibited a remarkable 94% lower rhinovirus presence compared to the placebo.
2. Symptom Ratings: Day-to-day symptom assessments illustrated that those using ColdZyme reported milder cold symptoms throughout their illness.
3. Sick Days: A marked decrease in the number of sick days was reported by the ColdZyme users, indicating fewer training disruptions due to colds.

As we move toward a future where preventive health measures are increasingly important, ColdZyme stands out as a pioneering solution, representing hope for those prone to respiratory infections. Enzymatica AB has highlighted the medical device’s EU MDR regulation certification (Class III), which underscores the safety and compliance standards upheld during its development.

Stay tuned for upcoming digital press briefings where researchers will delve deeper into these findings, scheduled for March 5, 2025. This product is administered as an oral spray utilized at the onset of cold or flu-like symptoms, marking a significant step in proactive health management.

For further information about ColdZyme, visit www.ColdZyme.se.